United Therapeutics has opened a new facility in Houston's Generation Park built to manufacture pig organs engineered for human transplant, a milestone the company says pushes it closer to supplying kidneys and hearts to patients who might otherwise die waiting for one. The facility, which opened Tuesday, is the company's third Designated Pathogen-Free production site, joining locations in Virginia and Minnesota.
A Third Facility Built for Scale
The new building is named the Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, according to BioSpace, which reported the facility is purpose-built to manufacture the company's xenokidneys and xenohearts. It sits at 11848 Common Dock Drive in Houston, as Community Impact reported, inside the sprawling Generation Park development. United Therapeutics opened its first Designated Pathogen-Free facility in Christiansburg, Virginia, in 2024, and its second in Stewartville, Minnesota, in August, per the same BioSpace account, giving the company three such sites nationwide.
The Stewartville and Houston facilities are designed, per the company's own description reported by BioSpace, to let United Therapeutics scale up commercial production of its xeno-organs if regulators approve the products. That distinction matters: the company has stressed that none of its investigational products has been cleared for use anywhere in the world.
Pigs With Ten Gene Edits
The xeno-organs at the center of the company's pipeline are organs transplanted from one species into another, and United Therapeutics is now running clinical trials on three of them: UKidney, UThymoKidney and UHeart, all aimed at patients facing heart and kidney failure. The UKidney and UHeart products come from pigs carrying 10 gene edits, including six added human genes and four inactivated pig genes, according to BioSpace's reporting on the announcement.
The EXPAND trial is a multicenter, open-label safety and efficacy study of UKidney in patients with end-stage renal disease, while the EXPRESS trial will start at a single center as a study of UHeart in patients with advanced heart failure, both according to Investing News Network. The FDA separately cleared United Therapeutics to proceed with a clinical study of the investigational UHeart product under the company's Investigational New Drug application, and earlier cleared a similar application to begin studying UKidney, according to United Therapeutics Investor Relations releases.
Facilities like the one that just opened in Houston require what Investing News Network described as a strictly controlled, biosecure barrier environment, including filtered air, filtered water, filtered feed supplies and decontamination entryways at every point of entry. The goal is to keep the pigs raised there free of pathogens that could complicate a future transplant into a human patient.
CEO Ties Opening to Transplant Waitlists
United Therapeutics Chairperson and CEO Martine Rothblatt said the facility and the company's ongoing clinical trials move the company closer to providing transplantable organs to people who need them, according to Community Impact's report on the opening. The framing points toward a documented gap between organ supply and demand: more than 103,000 patients are currently registered on U.S. organ waiting lists, and researchers writing in the journal Transplant International, as published by Frontiers Partnerships, put the toll at approximately 17 deaths a day among patients waiting for a suitable graft. The FDA's own xenotransplantation page cites a lower, differently sourced figure of ten deaths per day among patients awaiting vital organ transplants, a discrepancy the two sources do not reconcile.
The same Frontiers Partnerships research notes that genetically engineered pig organs have emerged as a promising strategy to close that gap, but that recent clinical progress has shifted the field's central challenge toward logistics — the production and distribution systems needed to actually get organs to patients at scale. The researchers argue that future xenotransplantation systems may end up resembling biopharmaceutical manufacturing networks more than the organ-donation system as it exists today, a shift the new Houston plant appears designed to anticipate.
Houston's Growing Biotech Cluster
The Houston facility lands inside Generation Park, a 4,300-acre master-planned community that Community Impact describes as home to a growing biotechnology hub. The development has drawn other major players: Eli Lilly and Company announced plans in September 2025 to build a $6.5 billion manufacturing facility there, a project expected to occupy 236 acres and bring more than 600 life sciences jobs to the park, according to Community Impact's earlier coverage. Bristol Myers Squibb has also selected Generation Park for a new $2.3 billion manufacturing campus, and the San Jacinto College Center for Biotechnology is located in the same development, which includes the 45-acre BioHub Two biomanufacturing campus that McCord Development unveiled plans for in 2023.
That buildout tracks with broader projections for the region. A March 2025 Cushman & Wakefield report found Houston already ranks 14th nationwide for total life sciences employment and projected the area's life sciences workforce to grow 76.5 percent over the following decade, per Community Impact's reporting.
Comparable Facilities Elsewhere
United Therapeutics' Minnesota facility offers a glimpse of what the Houston site may ultimately support. The company's $110 million Stewartville plant, known as the Thomas E. Starzl Xenograft Production Facility, was completed and readied to begin raising gene-edited pigs, according to the Post Bulletin. That 65,000-square-foot building has capacity for 150 pigs. Construction firm Mortenson, which partnered with United Therapeutics on an 80,000-square-foot Designated Pathogen Free Building in Stewartville, describes the project on its own site, though comparable size, cost or staffing figures for the new Houston facility were not available in company materials.
For now, the Houston opening marks another expansion point in a xenotransplantation field still defined by uncertainty — investigational products, ongoing trials, and a regulatory path that has not yet been completed in any jurisdiction. Whether the gene-edited pigs raised in Generation Park ever reach an operating room depends on results still to come from the EXPAND trial and the EXPRESS trial, which is set to start at a single center.
